Microbiota of Ustekinumab-treated Crohn's subjects.

The fecal microbiota is a rich source of biomarkers that have previously been shown to be predictive of numerous disease states. Less well studied is the effect of immunomodulatory therapy on the microbiota and its role in response to therapy. This study explored associations between the fecal microbiota and therapeutic response of ustekinumab (UST; STELARA®) treated Crohn's disease (CD) patients in the phase 2 CERTIFI study. Using stool samples collected over the course of 22 weeks, the composition of these subjects'' fecal bacterial communities was characterized by sequencing the 16S rRNA gene.